New thoughts about renaming nonalcoholic fatty liver disease / 临床肝胆病杂志

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) is a multisystem disease involving metabolic disorder and is more common in patients with obesity and type 2 diabetes mellitus (T2DM), with similar adverse outcomes to these two comorbidities. For a long time, NAFLD has emphasized liver lesions and outcomes of liver diseases, and when treating T2DM according to the current clinical guidelines for diabetes, endocrinologists often neglect the screening, diagnosis, and treatment of liver lesions. Therefore, in clinical practice, NAFLD renamed as metabolic-associated fatty liver disease has important practical significance. Strategies for T2DM prevention and treatment aiming at reducing liver lipid content require multidisciplinary cooperation, and prevention and treatment of obesity, fatty liver disease, and diabetes with the same concepts can help to implement the prevention and treatment of the most common chronic diseases.